Last updated 16 days ago
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
1100 patients around the world
Available in United States, Brazil
AstraZeneca
1100Patients around the world
This study is for people with
Bile Duct Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Histologically confirmed adenocarcinoma of the biliary tract, including intra-hepatic or extra-hepatic cholangiocarcinoma (CCA) and gallbladder carcinoma (GBC).Unresectable locally advanced or metastatic BTC, previously untreated in the advanced disease setting.Known PD-L1 status assessed at a central laboratory using an acceptable tumor sample.Measurable disease by RECIST 1.1 criteria using CT or MRI and is suitable for accurate repeated measurements.ECOG Performance Status of 0 or 1 with no deterioration (ie, ECOG PS > 1) over the previous 2 weeks prior to baseline at screening and prior to randomization.Adequate bone marrow and organ function.
- Ampullary carcinoma.Any prior systemic therapy received for unresectable, locally advanced or metastatic BTC.Any prior exposure to any other therapy targeting immune-regulatory receptors or mechanisms.Any concurrent chemotherapy, radiotherapy, immunotherapy, investigational, biologic, or hormonal therapy for cancer treatment other than those under investigation in this study.Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.Active or ongoing interstitial lung disease/pneumonitis (of any grade), serious chronic gastrointestinal conditions associated with diarrhea, or active non-infectious skin disease (including any grade rash, urticaria, dermatitis, ulceration, or psoriasis) requiring systemic treatment.
StudyARTEMIDE-Biliary02
SponsorAstraZeneca
Study typeInterventional
Conditions
Bile Duct Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07221253
